{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:02:20Z","timestamp":1788321740155,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.eplepsyres.2014.06.017","type":"journal-article","created":{"date-parts":[[2014,7,5]],"date-time":"2014-07-05T21:30:36Z","timestamp":1404595836000},"page":"1399-1405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study"],"prefix":"10.1016","volume":"108","author":[{"given":"Fernando D.","family":"Correia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Ramalheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Lopes-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2014.06.017_bib0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00126839-200304050-00001","article-title":"Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans","volume":"4","author":"Almeida","year":"2003","journal-title":"Drugs in R&D"},{"key":"10.1016\/j.eplepsyres.2014.06.017_bib0010","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/0091270004267591","article-title":"Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans","volume":"44","author":"Almeida","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2014.06.017_bib0015","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/0091270005279364","article-title":"Single dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects","volume":"45","author":"Almeida","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2014.06.017_bib0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093)","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.eplepsyres.2014.06.017_bib0025","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":"Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives","volume":"42","author":"Benes","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.eplepsyres.2014.06.017_bib0030","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res."},{"issue":"Suppl. 6","key":"10.1016\/j.eplepsyres.2014.06.017_bib0035","first-page":"S260","article-title":"The effects of eslicarbazepine, R-licarbazepine, oxcarbazepine and carbamazepine on ion transmission Cav3.2 channels","volume":"52","author":"Brady","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.06.017_bib0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1528-1167.2007.00984.x","article-title":"Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures","volume":"48","author":"Elger","year":"2007","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2014.06.017_bib0045","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.eplepsyres.2014.06.017_bib0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/bdd.549","article-title":"Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker","volume":"28","author":"Falcao","year":"2007","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.eplepsyres.2014.06.017_bib0055","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"Efficacy and safety of 800 and 1200mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.eplepsyres.2014.06.017_bib0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1528-1167.2012.03605.x","article-title":"Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Integrated analysis of pooled data from double-blind phase III clinical studies","volume":"54","author":"Gil-Nagel","year":"2013","journal-title":"Epilepsia"},{"issue":"2\u20133","key":"10.1016\/j.eplepsyres.2014.06.017_bib0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0920-1211(01)00231-5","article-title":"Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(\u2212)-10,11-dihydro-10-hydroxy carbamazepine","volume":"44","author":"Hainzl","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2014.06.017_bib0070","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1111\/j.1528-1167.2010.02660.x","article-title":"Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy","volume":"51","author":"Halasz","year":"2010","journal-title":"Epilepsia"},{"issue":"Suppl. 6","key":"10.1016\/j.eplepsyres.2014.06.017_bib0075","first-page":"S257","article-title":"Inhibitory effects of eslicarbazepine acetate and its metabolites against neuronal voltage-gated sodium channels","volume":"52","author":"Hebeisen","year":"2011","journal-title":"Epilepsia"},{"issue":"2\u20133","key":"10.1016\/j.eplepsyres.2014.06.017_bib0080","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.eplepsyres.2012.07.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study","volume":"103","author":"Hufnagel","year":"2013","journal-title":"Epilepsy Res."},{"issue":"Suppl. 6","key":"10.1016\/j.eplepsyres.2014.06.017_bib0085","first-page":"S257","article-title":"Effects of eslicarbazepine acetate and its metabolites in the corneal kindling model of epilepsy","volume":"52","author":"Pekcec","year":"2011","journal-title":"Epilepsia"},{"issue":"1\u20132","key":"10.1016\/j.eplepsyres.2014.06.017_bib0090","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.eplepsyres.2011.05.013","article-title":"Pharmacokinetics of eslicarbazepine acetate at steadystate in adults with partial-onset seizures","volume":"96","author":"Perucca","year":"2011","journal-title":"Epilepsy Res."},{"issue":"Suppl. 6","key":"10.1016\/j.eplepsyres.2014.06.017_bib0095","first-page":"S118","article-title":"Effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine and oxcarbazepine in the maximal electroconvulsive shock test in the mice","volume":"52","author":"Pires","year":"2011","journal-title":"Epilepsia"},{"issue":"Suppl. 6","key":"10.1016\/j.eplepsyres.2014.06.017_bib0100","first-page":"S119","article-title":"Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus","volume":"52","author":"Sierra-Paredes","year":"2011","journal-title":"Epilepsia"},{"issue":"Suppl. 6","key":"10.1016\/j.eplepsyres.2014.06.017_bib0105","first-page":"S257","article-title":"The effects of eslicarbazepine acetate in the amygdala kindling model of temporal lobe epilepsy","volume":"52","author":"Soerensen","year":"2011","journal-title":"Epilepsia"},{"issue":"Suppl. 6","key":"10.1016\/j.eplepsyres.2014.06.017_bib0110","first-page":"S118","article-title":"Effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine and oxcarbazepine in the 6-HZ psychomotor seizure model in the mice","volume":"52","author":"Torrao","year":"2011","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121114001752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121114001752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:32:15Z","timestamp":1760275935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121114001752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0920121114001752"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.06.017","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}